跳至主要内容
临床试验/CTRI/2023/10/058831
CTRI/2023/10/058831已完成2 期

Evaluation of the depigmenting effect of New Liftactiv B3 Melasyl serum (full-face) in patients with mild to moderate facial post-acne PIHP for 3 months. - NI

VICHY LABORATOIRES0 个研究点目标入组 112 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
112

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Subjects with various skin types, including normal, dry, oily, and combination,
  • 2. 50% of the subjects with self-declared sensitive skin
  • 3. Subjects with phototype III to VI (where all phototype will be enrolled in equal proportion for both the groups).
  • 4. Subjects with at least 2 epidermal spots that can be measured no dermal pigmentation as confirmed by Dermascopy/ wood’s lamp.
  • 5. Subjects with a minimum hair length of 10-15 cm.
  • 6. Subjects having mild active acne (less than 10 retentional and 5 inflammatory lesions).
  • 7. Subjects with mild to moderate facial post acne hyperpigmentation.
  • 8. Subjects who agree not to change their lifestyle during the study period.
  • 9. Subjects free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the face as determined by the dermatologist.
  • 10. Subject who agrees not to use any other product/treatment/home remedy/ except the provided product on their face during the study period other than the test product.
  • 11. Subjects who agree not to carry out bleaching or any other procedures including facial etc. on face during the study period.
  • 12. Subjects who agree not to expose to excessive sun light (sun exposure not more than half an hour daily and during that time use of umbrella to cover face).
  • 13. Subjects willing to give a voluntary written informed consent, photography release and agree to come for regular follow-up.
  • 14. Subjects willing to abide by and comply with the study protocol

排除标准

  • 1.Subjects suffering from severe acne.
  • 2.Subjects under topical or systemic retinoids.
  • 3.Subjec.ts under systemic immunosuppressants
  • 4. Subjects under active treatment of PIHP (including topicals or procedures) within the last 3 months.
  • 5. Subjects treated with facial procedures within the last 3 months
  • 6. Subjects diagnosed with Dermal melanosis by Dermascope
  • 7. Subjects diagnosed with Lichen Planus Pigmentosus.
  • 8. Subject with any other signs of significant local irritation or skin disease.
  • 9. Subject currently taking any medication, which the Investigator believes may influence the interpretation of the data.
  • 10. Subject having clinically significant systemic or cutaneous disease, chronic illness or had major surgery in the last year.
  • 11. Subjects who do not agree to remove all jewellery on/around face (e.g., necklace, earrings, if possible, nose ring), during VISIA CR imaging.
  • 12. Subjects having hair style which covers almost the entire forehead
  • 13. Subjects undergoing any treatment of any skin condition on their face
  • 14. Subjects not willing to discontinue other topical facial products.
  • 15. Subject allergic or sensitive to bar, cleansing products, cosmetics, creams/lotions, artificial jewellery or anything else.
  • 16. Subjects who are pregnant and lactating
  • 17. Subjects on any medical treatment either systemic/topical in the past 1 month or currently taking medication including food supplements.
  • 18. Subjects with skin allergy, history of atopic dermatitis or psoriasis
  • 19. Subjects who have participated in any other clinical trial in the last 3 months.
  • 20. Subjects using oral contraceptive pills or hormonal implants as birth control measures during the study
  • 21. Subjects who have undergone treatment with Botox/filler /bio stimulatory molecules injection.
  • 22. Subjects not able to provide Informed Consent and comply with the protocol

研究者

发起方
VICHY LABORATOIRES

相似试验